🇺🇸 FDA
Pipeline program

ST-503

ST-503-101

Phase 2 gene_therapy active

Quick answer

ST-503 for Chronic Neuropathic Pain is a Phase 2 program (gene_therapy) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).

Program details

Company
SANGAMO THERAPEUTICS, INC
Indication
Chronic Neuropathic Pain
Phase
Phase 2
Modality
gene_therapy
Status
active

Clinical trials